- Home
- EML vs OVID Comparison
EML vs OVID Comparison
Compare EML & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | OVID |
|---|---|---|
| Founded | 1858 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 117.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | EML | OVID |
|---|---|---|
| Price | $19.59 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | 9.5K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $6,610,000.00 |
| Revenue This Year | $1.56 | $1,081.80 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $18.90 | ★ N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $18.49 | $0.24 |
| 52 Week High | $31.67 | $2.01 |
Technical Indicators
Market Signals| Indicator | EML | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 68.57 |
| Support Level | $19.10 | $1.21 |
| Resistance Level | $20.11 | $1.56 |
| Average True Range (ATR) | 0.54 | 0.13 |
| MACD | 0.13 | 0.06 |
| Stochastic Oscillator | 60.83 | 94.55 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.